Zhongguo linchuang yanjiu (May 2024)
Comparison of the efficacy and safety of programmed cell death protein 1 inhibitors combined with albumin-paclitaxel with or without platinum in the treatment of advanced metastasis or recurrent cervical cancer
Abstract
Objective To compare the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor + albumin paclitaxel and platinum + PD-1 inhibitor + albumin-paclitaxel in the treatment of advanced metastasis or recurrent cervical cancer. Methods The clinical data of patients who had advanced metastatic or recurrent cervical cancer were treated with PD-1 inhibitor + albumin paclitaxel + platinum (group A) or anti-PD-1 + albumin-bound paclitaxel (group B) in more than second-line therapy in the Affiliated Cancer Hospital of Nanjing Medical University from September 2018 to December 2022 were retrospectively analyzed. The objective response rate (ORR), progression-free survival (PFS) and the incidence of adverse reactions between the two groups were compared. Results A total of 54 patients were collected, 37 in group A and 17 in group B. The median age was 53 years old, and the average follow-up time was 10 months. Among the patients, 45 cases were squamous cell carcinoma, 6 cases were adenocarcinoma, 1 case was adenosquamous carcinoma, and 2 cases were neuroendocrine small cell carcinoma. There was no statistically significant difference in the ORR between group A and group B (35.30% vs 35.14%, P>0.05). There was no statistical significant difference in PFS between group A and group B (11.7 month vs 7.3 month, P>0.05). The differences in the incidence of adverse reactions, the incidence of adverse reactions with grade 3 and above, and the incidence of immune-related adverse reactions between the two groups were not statistically significant (P>0.05). Conclusion The PD-1 inhibitor + albumin paclitaxel + platinum regimen does not increase the efficacy compared with the PD-1 inhibitor + albumin paclitaxel regimen in more than second-line therapy of advanced metastatic and recurrent cervical cancer.
Keywords
